Summary Insulin promoter factor 1 (IPF1) is a key factor both for the regulation of insulin gene expression and for the development of the pancreas. In this study 88 patients with non-insulin-dependent diabetes mellitus (NIDDM) who were diagnosed as diabetic at less than 40 years of age, 55 patients with insulindependent-diabetes (IDDM), and 67 normal control subjects were analysed for variants in the upstream region of the IPF1 gene by direct sequencing. A novel single nucleotide insertion polymorphism was found in a guanine triplet at 108 bp upstream of the translation start site. The G insertion allele (G4 allele) was found to be common in the Japanese population, at a frequency of 0.50. The prevalence of G3 homozygotes was higher in IDDM patients (35 %) and lower in NIDDM patients (17 %) than in normal control subjects (28 %, p = 0.049). In the NIDDM group, the ratio of insulin treatment tended to be higher in subjects homozygous for the G3 allele, although the genotype was not significantly associated with basal Cpeptide levels. The polymorphism is unlikely to be a major contributor to the insulin deficiency of diabetes. However, the polymorphic locus, or an unknown mutation which is in linkage disequilibrium with the polymorphism, could be involved in the pathophysiology of diabetes. The high heterozygosity may be useful for genetic linkage studies of other mutations within and near the IPF1 gene. [Diabetologia (1998) 
41: 603±605]
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predisposition to diabetes, we analysed the IPF1 gene using polymerase chain reaction (PCR) and a direct sequencing method.
Subjects and methods
We studied a group of 210 Japanese subjects comprising 88 patients with NIDDM, 55 patients with insulin-dependent diabetes mellitus (IDDM) and 67 control subjects. All patients with NIDDM (66 men and 22 women), had been diagnosed as having diabetes at less than 40 years of age. IDDM patients aged 26.8 ± 14.6 years (mean ± SD) consisted of 21 men and 34 women. Control subjects were found to have normal glucose tolerance in a 75 g oral glucose tolerance test according to World Health Organization criteria. We recruited normal subjects aged 50 years or more to exclude prediabetic subjects.
Amplification of the IPF1 upstream sequence and a part of exon 1 was performed by PCR in a 10 ml volume containing 1.5 mmol/l MgCl 2 , 0.25 U of AmpliTaq Gold DNA polymerase (Perkin Elmer, Branchburg, N. J., USA), and 5 pmol of the following oligonucleotide primers: 5 ¢-TACCTGGGCCTAGC-CTCTTA-3 ¢ and 5 ¢-CCCATGTACAGGCACGCAGG-3 ¢. After 9-min pre-heating at 96°C, amplification was carried out for 35 cycles; each cycle consisting of denaturation at 94°C for 1 min, annealing at 63°C for 1 min, and extension at 72°C for 1 min. Cycle sequencing of PCR products was performed using both sense and antisense primers in different reactions with AmpliTaq DNA polymerase and dichlororhodamine dye terminaters (Applied Biosystems, Foster City, Calif., USA). After removal of excess dye terminators with Centri-Sep spin columns (Princeton Separations, Adelphia, N. J., USA), samples were electrophoresed and analysed on an ABI Prism 310 automated sequencer (PE Applied Biosystems).
Statistical analysis. The results are presented as means ± SD. Differences between group means were estimated by the Kruskal-Wallis test. The chi-square test was used to compare frequencies. A p value less than 0.05 was considered statistically significant.
Results
We analysed 343 bp of the IPF1 gene including 247 bp of the 5 ¢ untranslated region and 96 bp of exon 1 by PCR and direct sequencing. A novel single nucleotide insertion polymorphism was identified in a guanine triplet at 108 bp upstream of the translation start site. The insertion of a guanine nucleotide (GGG®GGGG) in heterozygous and homozygous states is shown in Fig. 1 . The G insertion allele (G4 allele) was common in the Japanese population, at a frequency of 0.50 (Table 1 ). The G4 allele frequency was slightly higher in patients with NIDDM (0.53), and slightly lower in IDDM (0.44), although it did not reach statistical significance. When comparing the distribution of genotypes among NIDDM, IDDM and normal subjects, the prevalence of G3 homozygotes was higher in IDDM patients (35 %) and lower in NIDDM patients (17 %) than normal control subjects (28 %) (p = 0.049, G3/G3 vs G4/X).
In the NIDDM group, 8 of 15 patients homozygous for the G3 allele (53 %), 24 of 52 heterozygous patients (46 %), and 7 of 21 individuals homozygous for the G4 allele (33 %) were receiving insulin therapy (NS). Basal C-peptide levels in G3 homozygotes, heterozygotes, and G4 homozygotes were 1.5 ± 1.1, 2.1 ± 1.4, and 2.0 ± 1.8 ng/ml, respectively (NS). No significant association was observed between the genotypes of the IPF1 gene and the age of diagnosis, body mass index, serum lipid levels, or blood pressure, either in NIDDM patients or in IDDM patients. No other nucleotide alterations were found in the region studied in this study.
Discussion
IPF1 is a key factor both for the regulation of insulin gene expression and for the development of the pancreas. IPF1-containing stem cells are essential for beta-cell regeneration after injury in pancreatic islets [5] . Decrease of the IPF1 content in beta cells exposed to supraphysiological levels of glucose is considered to be a mechanism for glucose toxic effects on the beta cells leading to defective insulin secretion and worsening of hyperglycaemia [6] . Thus, IPF1 is a plausible candidate gene for NIDDM and non-autoimmune IDDM. Inoue et al. [2] analysed the homeodomain region in exon 2 by PCR and single-strand conformation polymorphism, and found no aberrant In this study we identified a single nucleotide insertion polymorphic site in the upstream untranslated region. Neither the NIDDM patients nor the IDDM patients showed a significant difference in the allele frequency when compared with normal control subjects. Hence the polymorphism is unlikely to make a major contribution to the insulin deficiency of diabetes. However, a borderline significant difference was found in the prevalence of G3 homozygotes among patients with NIDDM, patients with IDDM, and non-diabetic subjects; the frequency of the G3/G3 genotype was higher in IDDM than in NIDDM patients. In the NIDDM group, the ratio of insulin treatment tended to be higher in subjects homozygous for the G3 allele. These observations suggest that the polymorphic locus, or an unknown nearby mutation with which the polymorphism is in linkage disequilibrium, may influence the expression of the IPF1 gene, and thus play a role in the pathophysiology of diabetes.
Although further investigations are required to determine the functional significance of the polymorphism in diabetes, the high heterozygosity (50 %) may be useful for genetic linkage studies of other mutations within and near the IPF1 gene.
